Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from GENinCode UK Ltd. ( (GB:GENI) ).
GENinCode has announced the inclusion of its CARDIO inCode test in the US CMS 2025 Clinical Lab Fee Schedule, facilitating Medicare and Medicaid reimbursement and marking a significant step in US expansion. Additionally, the company is launching CARDIO inCode in Catalonia, Spain, aiming to improve cardiovascular disease risk assessment in primary care, with plans for further expansion in Spanish regions, underscoring its global impact on heart disease prevention.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based company specializing in genetic risk assessment for cardiovascular disease prevention. The company operates in the UK, Europe, and the United States, utilizing predictive technology with in vitro diagnostic molecular tests to provide advanced patient risk assessment strategies.
YTD Price Performance: -15.79%
Average Trading Volume: 64,479
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £5.66M
For detailed information about GENI stock, go to TipRanks’ Stock Analysis page.
